Related Experiment Video
Updated: Aug 9, 2026
06:26
Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
Published on: July 18, 2025
Inherited metabolic liver disease
Michael L Schilsky1, Scott Fink
1Center for Liver Disease and Transplantation, Division of Gastroenterology and Hepatology, New York Weill Cornell Medical Center, New York, USA. mls2003@med.cornell.edu
Current Opinion in Gastroenterology
|March 22, 2006
Summary
Genetic hemochromatosis, Wilson's disease, and alpha1-antitrypsin deficiency involve defects in cellular transport mechanisms. Understanding these molecular defects offers new therapeutic strategies for inherited metabolic diseases.
Area of Science:
- Hepatology and Genetic Metabolic Diseases
- Molecular Biology and Genetics
- Disease Pathogenesis
Background:
- Significant advancements in understanding the molecular basis of genetic hemochromatosis, Wilson's disease, and alpha1-antitrypsin deficiency over the past decade.
- Continued progress this year in molecular biology, genetics, epidemiology, and management of these inherited metabolic disorders.
Purpose of the Study:
- To review recent progress in the molecular biology, genetics, epidemiology, and management of genetic hemochromatosis, Wilson's disease, and alpha1-antitrypsin deficiency.
- To elaborate on the molecular mechanisms underlying these inherited metabolic diseases.
Main Methods:
- Review of recent scientific literature on genetic hemochromatosis, Wilson's disease, and alpha1-antitrypsin deficiency.
- Analysis of molecular biology, genetics, and pathophysiology of these diseases.
Main Results:
- Wilson's disease and genetic hemochromatosis are characterized by defects in heavy metal transport and accumulation in hepatocytes.
- Alpha1-antitrypsin deficiency involves the intrahepatic accumulation of defective alpha(1)-antitrypsin.
- Evolving understanding of protein and gene interactions in transport mechanisms, explaining disease phenotypes.
- Elucidation of molecular pathophysiology leading to novel clinical management strategies.
Conclusions:
- Recent developments highlight the critical role of genetic machinery defects in disease pathogenesis.
- A deeper comprehension of these genetic defects paves the way for potential new therapeutic interventions.
- The paradigm shift towards understanding genetic cellular machinery offers promising avenues for future treatments.
Related Concept Videos
01:20Inborn Errors of Metabolism
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
01:26Diseases of the Liver and Gallbladder
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
01:29Hepatic Encephalopathy
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...